is RETIRED
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The fact that David Taft and his investors have demonstrated confidence in the halloysite project by providing additional capital is reason for optimism. The value of an AMNL share has increased in value by over 25% IN THE LAST 30 DAYS.
As soon as a major sale of product is reported the stock should
really take off. Management had expected that major sale in the last half of 2010, but rather than being disappointed they have intensified their efforts to market their product.
NO SALES FOR 2010!!!
2010 Revenue:
halloysite products $110,339
Cambotexs products 201,556
The Cambotex figure must be a major disappointment.
As of April 12, 2011 there were 238,616,477 shares issued and outstanding. The Close on that day was $0.002. The market cap for NaturalNano was $477,233.
The Company has found that there is no market for their halloysite clay. They had had high hopes for sales this past 6 months. They said they were prepared to fill the orders.
The Company has now hired a CTO, Chris Dearmitt to create a market. Check him out at Linkedin.com. He is not a modest fellow. Hopefully he can do the job.
Last PPS: $0.32
Issued & Outstanding: 39,850,242
Conversion of Debentures: 2,715,285
Warrants: 12,318,481
Options: 2,480,000
Fully Diluted: 57,364,008
The new financing will increase the issued and outstanding by
13,333,334 shares and a like number of 2 year warrants priced at C$ 0.40
The immediate cash inflow should be near C$ 4,000,000.
Right?
How far should that take us?
"A completed paradigm shift for VADS in advanced HF: The INTERMACS registry at 5 years.......
Currently, there are 109 centers actively participating INTERMACS and almost 3,500 patients logged into the registry. It should be noted that for centers to comply with CMS and to be reimbursed when a device is placed as a “destination home-permanent” therapy, they must be a participant in good standing with INTERMACS and report their data responsibly. An early analysis of INTERMACS revealed a slow but steady patient accrual that significantly increased when the HeartMate II (Thoratec) continuous flow device was approved by the FDA mid-year 2008 as a bridge to cardiac transplantation. This rather dramatic change in the number of patients undergoing MCSD implantation appeared constant and was likely driven by the fact that the newer device was a dramatic improvement over previous pulsatile MCSD choices. This was the beginning of the paradigm shift. Whereas most funding, development efforts and patient experience had previously focused on pulsatile devices, the science (and then clinical approach) to the patient changed.
Outcomes after MCSD implantation
INTERMACS demonstrates that survival after MCSD insertion using contemporary pumps is reasonable and steadily improving with incremental advances in the devices. As one may expect, improved outcomes were noted with intracorporeal continuous flow systems that were used as an LVAD. One competing outcomes analysis demonstrated that at 6-months follow-up, the likelihood of survival or heart transplant was higher with continuous flow devices than with pulsatile machines (88% vs. 80%). Still unknown is whether this difference will hold up with longer-term follow-up.
Another important observation that can be made is that removal of these devices due to “adequate recovery of myocardial function” that is believed adequate enough to handle the entire burden of circulatory demand (also called “bridge-to-recovery”) is rare, occurring in about 1% of patients. This observation emphasizes that the concept still needs tremendous work to clarify, if there is any reality to the concept to begin with......."
by James B. Young M.D. in "Cardiology today" 11-1-2010
Please estimate for us if you would how much of today's volume of 16,957,700 shares was day trading. Would it figure based on the trade data that someone is taking a large position in this Company. Technology Innovations, LLC, TI's warrant will expire shortly and is priced well over today's PPS. They could be buying on the open market if they want to go forward with halloysite products.
Historical Prices
Date Open High Low Close Volume Adj
Close
2010/12/21 0.0025 0.0045 0.0025 0.0028 13,339,944 0.0028
2010/12/20 0.0037 0.0048 0.0031 0.0034 2,044,578 0.0034
2010/12/17 0.0046 0.0046 0.0031 0.0037 5,797,226 0.0037
2010/12/16 0.0070 0.0080 0.0045 0.0050 14,071,429 0.0050
2010/12/15 0.0050 0.0085 0.0050 0.0065 36,576,733 0.0065
2010/12/14 0.0030 0.0074 0.0030 0.0045 21,079,384 0.0045
How many of its 20,000,000 NNAN shares did Worldwide Medical Solutions sell in the past 6 days?
Did the lenders sell all their shares received this year for
interest on their loans - over 23,000,000?
How much of the volume the last 6 days was day trader action?
"It is true that in Tintic the mines are no longer operating on the grand scale of the past but exploration, core drilling small operations keep hope alive. There is still much of the old mining past that could easily be made accessible to many who would love to see "the way it used to be." While the mountains around Eureka and the weather may not be suited for skiing, the old trails, stagecoach routes and railroad grades could be ideal for hiking and mountain biking.
The flow of wealth from the area was once pivotal in helping to get this great state on its feet and put life into a struggling economy. It is where the Mormon Church and hard rock mining (traditionally been the domain of the "gentile" population) finally came to grips with one another. The Tintic Mining District has a history and story like no other. Cowboys, Indians, gunfighters, outlaws, prostitutes, miners, Mormons ... Tintic had it all! With careful planning, a lot of hard work and some visionary leadership, there could still be a great future ahead for this unique mining district, a place that that has given so much to the State of Utah"
MyoCardioCare, Inc. Appoints Appoints Renowed Surgeon Dr. Gus Vlahakes to Scientific Advisory Board
ROCHESTER, NY, November 17, 2010 -- MyoCardioCare, Inc., a medical device company which is commercializing innovative, life-saving, acute circulatory support systems for patients in cardiac arrest, announces the appointment of Dr. Gus J. Vlahakes to its Scientific Advisory Board. Dr. Vlahakes will be providing clinical guidance in the development of MyoCardioCare’s next-generation technologies.
He has been on the Staff at Massachusetts General Hospital for the last 25 years, and has been involved with mechanical circulatory support since 1987. He has been principle investigator on numerous clinical trials of circulatory support devices during his tenure on the staff at Massachusetts General Hospital.
John F. Lanzafame, President of MyoCardioCare, commented, “We are excited to welcome Dr. Vlahakes to MyoCardioCare’s Scientific Advisory Board. His leadership in the field of cardiac surgery and his extensive experience with circulatory support devices will provide great insight as we commercialize the MCC3000."
Dr. Vlahakes is an engineering graduate of MIT and received his MD degree from Harvard Medical School. He received his general surgery and cardiothoracic surgical training at Massachusetts General Hospital and Boston Children's Hospital. He completed a three-year cardiac physiology fellowship at the Cardiovascular Research Institute at the University of California, San Francisco.
Dr. Vlahakes is joined on the MyoCardioCare’s Scientific Advisory Board by Dr. Brian Gibler who was recently appointed President & CEO of the University of Cincinnati Hospital and Senior Vice President of UC Health.
About the MCC3000 and MyoCardioCare, Inc.
MyoCardioCare is commercializing an innovative heart pump that has the potential to save millions of lives. The device, the MCC3000, is the first in a family of products based upon Direct Mechanical Ventricular Actuation (DMVA) technology. It consists of a flexible polymer "cup" that can be installed around the heart in under five minutes. Incorporating a pneumatically activated liner, the MCC3000 operates by compressing and expanding bi-directionally, providing the energy that allows the heart to restore the blood flow to normal, life-sustaining levels. A previous version of the technology had helped save human lives in emergency-use situations by providing circulatory support to patients for between 2 and 83 days.
The MCC3000 energizes the best blood pump known to man: the human heart. Since it does not contact circulating blood, as do virtually all existing cardiac assist devices, the MCC3000 has the potential to reduce or avoid complications which plague existing devices, including clotting, stroke, bleeding, and infection. Additionally, the healing environment created by the MCC3000 has the potential to rehabilitate many sick hearts, allowing the device to be removed and the heart to function properly again without assistance.
The first generation of the MCC3000 to be introduced will enable the trained physician to quickly restore cardiac function and blood flow to resuscitate cardiac arrest patients. This procedure could be performed in life-saving emergency situations in hospitals around the world.
For more information about MyoCardioCare, Inc. please visit our website at www.myocardiocare.com.
Last Price $0.0035 Today's Change -0.0002 (-5.41%) Today's Volume 1,921,150 at 12:00 PM PST
UNITI LLC, an industrial titanium venture jointly owned by Allegheny Technologies Incorporated (NYSE: ATI) and Verkhnaya Salda Metallurgical Production Association (VSMPO), today announced that it has been chosen to supply a significant portion of the commercially pure (CP) titanium to be used in the world’s largest seawater desalination plant.
UNITI expects to supply between 5.5 million and 6.0 million pounds of CP titanium strip that will be used to produce titanium tubing for the project. This is the largest order in UNITI’s history. Shipments are planned to be spread evenly throughout 2011.
UNITI’s customer, Doosan Heavy Industries & Construction of Korea, was selected by the Saline Water Conversion Corporation (SWCC) for a seawater desalination project to be built in Ras Az Zawr, Saudi Arabia. The plant’s daily potable water output will be the largest in the world, sufficient to meet the needs of 3.5 million people.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on management's current expectations and include known and unknown risks, uncertainties and other factors, many of which we are unable to predict or control, that may cause our actual results, performance or achievements to materially differ from those expressed or implied in the forward-looking statements. Additional information concerning factors that could cause actual results to differ materially from those projected in the forward-looking statements is contained in Allegheny Technologies' filings with the Securities and Exchange Commission. We assume no duty to update our forward-looking statements.
Allegheny Technologies Incorporated is one of the largest and most diversified specialty metals producers in the world with revenues of $3.8 billion for the twelve months ending September 30, 2010. ATI has approximately 8,900 full-time employees world-wide who use innovative technologies to offer global markets a wide range of specialty metals solutions. Our major markets are aerospace and defense, oil and gas/chemical process industry, electrical energy, medical, automotive, food equipment and appliance, machine and cutting tools, and construction and mining. Our products include titanium and titanium alloys, nickel-based alloys and superalloys, grain-oriented electrical steel, stainless and specialty steels, zirconium, hafnium, and niobium, tungsten materials, and forgings and castings. The Allegheny Technologies website is www.ATImetals.com.
“I’m very excited about it because I know it works.
It’s going to save a lot of lives.” Dr. James E. Lowe, MD, Professor of Surgery and Pathology, Duke University Medical Center
When was it said and does he still believe it to be true?
The web site dukehealth.org/physicians/james-e-lowe has Dr. Lowe's comment:
"Our major applied research project is designed to develop a totally implantable biventricular, non-blood contacting cardiac assist device which we have termed, "Direct Mechanical Ventricular Actuation" (DMVA). DMVA is a non-blood contacting method for circulatory support which can be used in the failing heart, asystolic heart and fibrillating heart. The technology utilizes a contoured cup which attaches itself to both ventricles through a small anterior thoracotomy via a continuous vacuum. Once attached, positive and negative pneumatic forces move a diaphragm within the assist cup to "actuate" the ventricles into respective systolic and diastolic configurations. Recent advances
---------------
in support cup design and drive-line mechanics strongly suggest
---------------------------------------------------------------
that the technology can be further developed to provide safe, effective and economical long-term circulatory support with numerous advantages over blood-contacting cardiac support devices."
MyoCardioCare was created to commercialize an innovative heart pump that has the potential to significantly improve these results:
Every two minutes in the United States, a person’s heart stops beating. Standard therapies include CPR, defibrillation and medical therapies, which may not be effective in resuscitating these patients. Roughly 80 percent of patients suffering cardiac arrest in a hospital do not survive to discharge despite the best efforts of trained medical personnel.
The MyocardioCare web pages.
The CEO tried to obtain authorization to issue additional BIPH shares to finance ongoing development of the myovad product.
He failed in that effort. He could have closed the doors,
but instead he sold the product candidate and obtained a 20% interest for the Biophan shareholders in the buying company. He had turned debt into equity interest in the past, and he did that in this transaction.
Authorized, 250,000,000 Common Stock, $.005 par value:
Class outstanding as of July 25, 2008 174,709,892
Class outstanding as of October 10,2008 243,285,264
Class outstanding as of January 16,2009 243,285,264
If the product fails it will not be for lack of trying. If the odds were good some big company would have bought it long ago.
Here is the resume of one of those persons.
Mark P. Anstadt, M.D, FACS
Associate Professor, Surgery
Associate Professor, Pharmacology & Toxicology
Chairman, Cardiothoracic Surgery
Vice Chairman, Department of Surgery
Medical Director, Cardiothoracic Services
Miami Valley Hospital
Address: Miami Valley Heart & Lung Surgeons, LLC, 30 East Apple St. Suite 6252, Dayton, OH 45409
e-mail: mark.anstadt@wright.edu
--------------------------------------------------------------------------------
Education:
B.S., Animal Biosciences, Pennsylvania State University, State College, PA (1982)
M.D., Wright State University School of Medicine, Dayton, OH (1986)
Residency (General Surgery, Internship & R1), Ohio State University Hospital, Columbus, OH (1986-1988)
Research Fellowship (Cardiothoracic Surgery) Duke University, Durham, NC (1988-1993)
Residency (General Surgery, R2-5) Duke University, Durham, NC (1993-1996)
Fellowship (Cardiothoracic Surgery) Duke University, Durham, NC (1996-1998)
Research Interests:
Current Research: Functional and Molecular Affects of Direct Mechanical Ventricular Actuation on the Failing Heart
ABSTRACT: Mechanical circulatory support (MCS) devices use blood-contacting pumps to channel blood around the ventricular chambers. Unfortunately, blood contact carries significant risks including thromboembolism, bleeding, immune suppression, and activation of the inflammatory system. Direct mechanical ventricular actuation (DMVA) is a non-blood contacting MCS device that augments systolic and diastolic function. DMVA can reduce myocardial wall stress and improve blood flow without contacting the blood. Clinical experience has shown the device can support the failing heart for up to three months. Recent investigations demonstrate that DMVA attenuates: heat shock proteins, matrix metalloproteinase activity and myocardial cell membrane wounding in an experimental model of acute heart failure. Ongoing work is focused on evaluating DMVA’s effect on myocardial function and maladaptive cellular responses in the failing heart.
Novel to these investigations are (a)the unique aspects of a clinically relevant non-blood contacting MCS device which has been tested in humans, (b)the use of cutting-edge echocardiographic technology (velocity vector imaging) to interrogate myocardial funtion (c) correlations of myocardial function and DMVA support with molecular and cellular cell signals.
Previous & Ongoing Research Activities
1.Circulatory support/ emphasis on non-blood contact heart pumps.
2.Echocardiographic analysis of ventricular function emphasis on VVI.
3.Resuscitation with emphasis on cerebral blood flow and mechanical circulatory support.
4.Molecular and cellular effects of circulatory support on myocardium (i.e. apoptosis, ventricular remodeling, and myocardial stress).
5.Vascular function of cardiopulmonary bypass graft with emphasis on endothelian and matrix metalleoproteinases.
Recent Abstracts & Presentations
Wozniak CJ, Pothoulakis AJ, Gargac SM, Darner RJ, Anstadt MP: Utility of Velocity Vector Imaging in the Assessment of Cardiac Function in the Norma and Failing Heart. Presented at the 18th Annual Scientific Sessions of the American Society of Echocardiography, Seattle, WA, June, 2007.
Wozniak CJ, Gargac SM, Pothoulakis AJ, Prochaska LJ, Darner RJ, Kerns S, Budharaju S, Anstadt MP: Non-blood contacting Mechanical Support of the Pediatric Failing Heart. Presented at the Third International Conference on Pediatric Mechanical Circulatory Support Systems and Pediatric Cardiopulmonary Perfusion Annual Meeting, Hershey, PA, May 2007.
Wozniak CJ, Pothoulakis AJ, Gargac SM, Darner RJ, Anstadt MP: Velocity Vector Imaging Characterizes Systolic and Diastolic Augmentation of the Failing Heart During Non-Blood Contacting Ventricular Actuation. Presented at the American College of Cardiology Annual Meeting, New Orleans, LA, March 2007.
Wozniak CJ, Campbell AM, Gargac SM, Darner RJ, Anstadt MP: Non-blood Contacting Biventricular Mechanical Actuation of the Failing Heart. Presented at the American Association of Thoracic Surgery/Cleveland Clinic Kaufman Symposium of 21st Century Treatment of Heart Failure, October 2006.
Anstadt MP, Franga D, Caldwell W, Ergul A: Mechanical Cardiac Actuation of the Failing Heart Reduces Matrix Metalloproteinases Activity. ASAIO Journal, Vol 52(2), 61A, 2006.
Anstadt MP, Lowe LE: Cardiopulmonary Resuscitation. In Cardiac Surgery in the Adult, Cohn (ed), 3rd Edition: IN PRESS, 2006.
Ergul A, Johansen JS, Strømhaug C, Harris AK, Hutchinson J, Tawfik A, Rahimi A, Rhim E, Wells B, Caldwell RW, Anstadt MP. Vascular Dysfunction of Venous Bypass Conduits Is Mediated by Reactive Oxygen Species in Diabetes: Role of Endothelin-1. JPET 2005;313:70-77.
Anstadt MP, Franga DL, Portik-Dobos V, Pennathur A, Hutchinson J, BannanM, Mawulawde K, Ergul A. Native Matrix Metallaproteinase Characteristics May Influence Early Stenosis of Venous Versus Arterial CABG Conduits. CHEST 2004;125:1853-1858.
Franga DL, Wicker DL, White S, Yuan J, El-Ramace A, Caldwell W, Anstadt MP: Direct Cardiac Compression Attenuates Myocardial Stress and Injury in the Acutely Failing Heart. J Am Coll of Surg, Vol 197(3), pS25, Sept 2003.
Anstadt MP, Schulte-Eistrup SA, Motomura T, Soltero E, Takano T, Mikati IA, Nonaka K, Joglar F, Nosé Y. Non-Blood Contacting Biventricular Support Synchronized to the Failing Heart. Ann Thor Surg 2002;73:556-562. [Abstract]
"They cannot moderate based on that opinion however."
Yes they can and the NaturalNano board proves it. So why not tell us what we can do about it? If nothing, say so please.
The 12/9/2010 Applied Minerals press release (Applied Minerals, Inc. and KibbeChem, Inc. Announce a Joint Development and Masterbatch Manufacturing Agreement) is linked on the KibbeChem, Inc. web page (www.kibbechem.com/). KibbeChem is profiled by Manta as "Kibbechem, Inc is a private company categorized under Foam Charge Mixtures and located in Elkhart, IN. Our records show it was established in 1990 and incorporated in Georgia. Current estimates show this company has an annual revenue of 3,900,000 and employs a staff of approximately 28."
KibbeChem states on its wep page: "A specialist in the plastics industry since 1990, KibbeChem provides global coverage through its two manufacturing facilities and commercial centers based in Elkhart, Indiana and Las Vegas, Nevada. With regional sales offices able to service customers throughout North America, our multiple locations offer faster shipping times, and allow your company to better manage just-in-time inventory."
HALT IN TRADING IMA.V AT COMPANY REQUEST
Press Release Source: Investment Industry Regulatory Organization of Canada (IIROC); Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions On Wednesday December 1, 2010, 10:06 am
VANCOUVER, Dec. 1 /CNW/ - The following issues have been halted by Investment Industry Regulatory Organization of Canada (IIROC):
Issuer Name: i-minerals inc. TSX-V Ticker Symbol: IMA Time of Halt: 9:59 e.t. Reason for Halt: Company Request Pending News
For further information
IIROC Inquiries (416) 646-7299 - (x)Please note that IIROC is not able to provide any additional information regarding a specific trading halt. Information is limited to general enquiries only.
Senetek PLC Embarks on New Strategic Direction
Company Completes $3.0 Million Financing
Chief Executive Officer and Chief Financial Officer Terminated in Connection with Financing
John P. Ryan Appointed Chief Executive Officer in Connection with Financing
Board of Director Resignations and Appointments in Connection with Financing
Company Exits Skin Care Business in Connection with Financing
NAPA, Calif., March 10 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY) today announced the closing of a Security Purchase Agreement, a Note and a Warrant Purchase Agreement DMRJ Group, LLC on March 4, 2010. DMRJ Group, LLC is a Delaware limited liability company affiliated with Platinum Partners Value Arbitrage Fund L.P., an accredited institutional investor with its investment manager headquartered in New York, New York.
The Company issued a Secured Convertible Promissory Note to DMRJ in the principal amount of $3.0 million, which bears no interest and is convertible at a price of $1.25 per share at any time from inception to the fifth anniversary of the Note, at which time conversion is mandatory. Except in the event of default, the Note is not repayable in cash. In addition, the Company issued a five-year warrant to purchase 1.8 million of the Company's ordinary shares at an exercise price of $1.75 per share.
In connection with the financing and sale of the skin-care business, Frank J. Massino was terminated without cause as Chief Executive Officer and resigned as Chairman of the Board of Directors. Mr. Massino has been retained as a part-time consultant for a three year period to assist in management of certain of the Company's existing investments and interests. Also, in connection with the financing and sale of the skin-care business, William F. O'Kelly was terminated without cause as Chief Financial Officer and Mr. Rodger Bogardus resigned from the Board of Directors.
John P. Ryan has been appointed to succeed Mr. Massino as Chief Executive Officer and Chairman of the Board of Directors. Mr. Ryan has extensive management experience in the mining industry, and in the past has been Founder and Chairman of U.S. Silver Corporation, a Toronto Stock Exchange listed company, where he earlier served as Chief Financial Officer. Mr. Ryan was a Founder, Secretary and Chief Financial Officer of High Plains Uranium, from inception on February 2005 to September 2006. In collaboration with principals from Platinum, he was a founder and principal of Platinum Diversified Mining, a resource focused $85 million SPAC which listed on the London AIM in 2006. He received a B.S. degree in Mining Engineering from the University of Idaho and a JD from Boston College Law School.
In addition, Mr. Howard Crosby has been appointed to the Board of Directors and named President of the Company. Mr. Crosby has extensive experience working with public companies. He was a founding Director of White Mountain Titanium Corporation, a founder and Director of High Plains Uranium, and also a founder of Platinum Diversified Mining. He is currently the Chairman of Plasmet Corp., a private green energy company. Mr. Crosby graduated from the University of Idaho in 1974.
Dr. Wesley Holland has also been appointed to the Board of Directors. Dr. Holland has nearly 30 years of experience in diagnostic radiology. He was licensed in California from 1981 to 1994 and is currently licensed in South Carolina and in Florida. His specific expertise is in utilizing critical molecular and nuclear diagnostic imaging procedures to diagnose and treat disease and disorders such as heart disease and cancer.
The Company received reports on November 13, 2009 and on February 1, 2010 from Miller Tabak + Co., LLC, prepared in their capacity as financial advisors to the Board of Directors, which reviewed strategic options and the best means to development of a business plan to maximize the assets of the company. Observations made by Miller Tabak included the following:
•The Company's current businesses are all underfunded intellectual property assets that will require investments far in excess of existing Company resources to bring to the point where they would generate meaningful revenue.
•Establishment of competitive sales and marketing infrastructure generating meaningful revenue would require investment far in excess of existing Company resources.
•The Company has realized past success with intellectual property licensing but this business model is in disfavor with institutional investors which makes it difficult to create a viable market for the Company's stock.
•Skincare is a highly competitive, highly fragmented market with few barriers to entry for the over-the-counter and cosmetic market.
Based on these observations, Miller Tabak recommended that the Board develop a new business strategy to bring revenue, profits and a positive opportunity for Company shareholders. In addition, a condition precedent to the financing was the divestiture of the skin care business.
With consideration to the strategic review by Miller Tabak and the condition to the transaction with DMRJ, the Company executed an Asset Purchase Agreement and a Note with Skinvera LLC, a company wholly owned by Frank J. Massino, former Chairman and Chief Executive Officer of the Company, whereby Skinvera purchased all assets and assumed all existing liabilities of the Company's skincare business (except for assets and liabilities related to kinetin and zeatin) and received $1.8 million in cash in return for a $1.8 million Secured Promissory Note which bears interest at 6% per annum and is due on the seventh anniversary of the Note. The Asset Purchase Agreement includes provisions for royalty payments to the Company from Skinvera based on 5% of net direct sales of skincare products and 10% of net skincare royalties; up to a maximum of $5 million.
Mr. Ryan, Senetek's new Chairman and Chief Executive Officer, stated, "I am very pleased to have been given the opportunity to set a new business path for Senetek. Our team is currently evaluating a number of potential value creating transactions which are consistent with our focus to maximize shareowner value. I am also looking forward to working with the Board in optimizing the value of the biotech assets the Company currently holds. The sale of the skin-care assets is a first step in an ongoing process of finding good matches for our existing technology. As we develop a new strategic direction for the Company, we look forward to communicating our plans to our shareholders and the investment community."
This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2008 and subsequent Quarterly Reports on Form 10-Q. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.
SOURCE Senetek PLC
The largest NNAN trade today was at $.006 of 353,000 shares for $2,118. The total amount paid today for the 3,334,826 shares traded was about $25,000. The Bid at the Close was $.0075. The Ask was $.0088. Tomorrow should be very interesting. Perhaps we will become better informed as to what is happening.
Is NaturalNano going to buy the Dragon Mine?
The amendment of the articles of the Company to allow for the issuance of an unlimited number of shares did not receive the approval of the required 2/3 majority. "Unlimited" was a bit too much. How many additional shares do they need?
The new name is Ruheri Anthony Perez-Tamayo. I think you will find the info on this site very interesting: www.facs.org/fellows_info/bulletin/2009/eiferman0709.pdf
Does it appear to you that thay have found the fix?
If the fix has been found financing news should not be far behind.
MyoCardioCare, Inc. Appoints Internationally Recognized Dr. Brian Gibler to Scientific Advisory Board
Rochester, NY, September 23, 2010 -- MyoCardioCare, Inc., a medical device company which is commercializing innovative, life-saving, acute circulatory support systems for patients in cardiac arrest, announces the appointment of Dr. Brian Gibler to its Scientific Advisory Board. Dr. Gibler will be providing clinical guidance in the development of MyoCardioCare’s next-generation technologies. Dr. Gibler currently serves as the Richard C. Levy Professor of Emergency Medicine and Chairman of the Department of Emergency at the University of Cincinnati College of Medicine. He is also the Director for the Center of Emergency Care of the University of Cincinnati Hospital in Cincinnati, Ohio.
Dr. Gibler is an editor and referee for numerous Emergency Medicine and Cardiology journals and has published numerous peer-reviewed articles on the early diagnosis and treatment of Acute Coronary Syndrome in the Emergency Medicine and Cardiology literature. He is internationally known for his efforts in creating a multicenter trials group, the Emergency Medicine Cardiac Research Group (EMCREG)-International. He was also a member of the International GUSTO Trials Steering Committee and served as a member of the National Heart Attack Alert Program Working Group.
Frank W. Terrizzi, Chairman and CEO of MyoCardioCare, commented, "We are extremely pleased to have Brian Gibler, a well recognized and respected leader in the field of Emergency Medicine, join MyoCardioCare. We look forward to Dr. Gibler's contributions to our efforts to serve patients suffering from cardiac arrest."
John Lanzafame, President added, "I'm delighted to welcome Dr. Gibler to the MyoCardioCare team and look forward to working with him."
In 2008, the Board of Trustees of the Society of Chest Pain Centers bestowed upon Dr. Gibler the Raymond D Bahr Award of Excellence at the 11th Congress of Chest Pain Centers in Orlando, Florida. This award is given to individuals who demonstrate extraordinary vision, leadership, and excellence in advancing healthcare. In 1999, Dr. Gibler received the Hospital Hero Award from the Cincinnati Business Courier for his work on Chest Pain Centers. He has been voted to the Cincinnati Business Courier Best Doctor list from 2007-2010. In 1995, Dr. Gibler was awarded the Outstanding Contribution to Research Award from the American College of Emergency Physicians, and Best Original Research Paper at the 3rd International Conference on Emergency Medicine in Toronto, Canada in 1990.
Dr. Gibler's educational accomplishments include an M.D. from the Vanderbilt University Medical School, and a Sc.B. in Biology from Brown University where he graduated magna cum laude. Dr. Gibler is a graduate of the University of Cincinnati Emergency Medicine Residency Training Program.
About the MCC3000 and MyoCardioCare, Inc.
MyoCardioCare is commercializing an innovative heart pump that has the potential to save millions of lives. The device, the MCC3000, is the first in a family of products based upon Direct Mechanical Ventricular Actuation (DMVA) technology. It consists of a flexible polymer "cup" that can be installed around the heart in under five minutes. Incorporating a pneumatically activated liner, the MCC3000 operates by compressing and expanding bi-directionally, providing the energy that allows the heart to restore the blood flow to normal, life-sustaining levels. A previous version of the technology had helped save human lives in emergency-use situations by providing circulatory support to patients for between 2 and 83 days.
The MCC3000 energizes the best blood pump known to man: the human heart. Since it does not contact circulating blood, as do virtually all existing cardiac assist devices, the MCC3000 has the potential to reduce or avoid complications which plague existing devices, including clotting, stroke, bleeding, and infection. Additionally, the healing environment created by the MCC3000 has the potential to rehabilitate many sick hearts, allowing the device to be removed and the heart to function properly again without assistance.
The first generation of the MCC3000 to be introduced will enable the trained physician to quickly restore cardiac function and blood flow to resuscitate cardiac arrest patients. This procedure could be performed in life-saving emergency situations in hospitals around the world.
For more information about MyoCardioCare, Inc. please visit our website at www.myocardiocare.com.
Contact:
John Lanzafame, President
Phone: (877) 778-2696
Fax: (877) 778-2685
Applied Minerals, Inc. Announces $3,050,000 Financing
RealClearMarkets - AP - Markets - Oct 10, 2010 - Port of Lewiston ...
Oct 10, 2010 ... Port of Lewiston in business slump. Nicholas K. Geranios. The big barges and small cruise ships are almost a surreal sight as they sail past ...
www.realclearmarkets.com/...business/.../port_of_lewiston_in_business_slump.html
See the Combotexs web site: www.COMBOTEXS.COM.
It will be interesting to learn if he, Thomas M. Conway has an
investment in IMA shares.
SEE WWW:NORTHSTAR-HALLOYSITE.COM
It is frightening to realize that my purchase of 2000 IMAHF shares for under $600 had such an impact on the market value of the Company which is now up 13.55%.
I have no real knowledge of the Company. I am following the lead of Doubloom only because I suspect that he knows the upside potential of this mining venture, and
because I am willing the take the risks involved. I am a believer in the value of halloysite clay although I have yet to see a large market for the high end product.
Applied Minerals Inc. contends they are a producer of halloysite clay but they have not reported any sales nor have they stated an inventory in their financial statements.
I do expect a jump in the value of IMAHF shares in the near future, but am planning on taking a long journey with this venture.
Cancer Cell Capture Enhanced by NaturalNano's Naturally Occurring Halloysite Tubes.
NATURALNANO announced today that Dr. Michael King, a researcher at Cornell University, has published a new study demonstrating how NaturalNano nanotubes can improve targeting of circulating tumor cells (CTC's). These nanotubes, when added to the surface where cancer cells are attracted, enhance the natural rolling mechanism that Dr. King believes will allow them to be exposed to specific drugs or other therapeutic agents, or isolated for diagnostic and research purposes. Developed by Dr. King, this has significant potential for novel treatments in personalized medicine being developed at Cornell and elsewhere.
The study explores a method to more efficiently capture leukemic and epithelial cancer cells from the bloodstream by altering the nanoscale topography of the surface of P-selectin-coated capillary tubes. This is achieved by attaching naturally occurring halloysite nanotubes to the tube surface via a monolayer of poly-L-lysine. It has been found that halloysite nanotube coatings promote increased capture of leukemic cells. The article may be found online at http://pubs.acs.org/doi/abs/10.1021/la101179y
Michael King, Associate Professor of biomedical engineering at Cornell University, states, "The ability to create stable coatings of halloysite using an extremely thin layer of poly-L-lysine gives us a way to create nanostructured surfaces that living cells respond to. This breakthrough could impact a number of projects we have been working on for basic research and diagnostic detection of circulating tumor cells in blood."
.......
SEE THE NEW WEB SITE: www.appliedminerals.com
Re the company's website:
It would be helpful if management would have the share structure on their website updated. The information now shown is as of October 21. 2008.
The hold period in Canada ends on May 30, 2010 for the securities issued in the Canaccord financing that was announced on 2/1/2010.
Authorized Shares of AMNL:
"As of April 19, 2010, the Company had:
· 120,000,000 authorized shares of Common Stock;
· 67,084,579 issued shares of Common Stock
· 79,838,279 issued shares of Common Stock on a fully-diluted basis when accounting for the exercise of outstanding stock options and warrants and the conversion of 10% PIK Election Convertible Notes 'PIK Notes'."
The market cap at $0.80 a share is near $64,000,000.
"Richard M. Popovic is the President of Study International and has been the President or Chief Executive Officer of a number of education driven small companies including Indelta Learning Systems, LLC and WorldWide Medical Solutions, LLC.
Mr. Popovic brings 20 years of corporate management, strategy, and training experience. In addition, he has 10 years of academic experience as the Dean for Executive Programs internationally, Director for Medical Management Education and Professorial Lecturer at the William E. Simon Graduate School of Business at the University of Rochester. He has also acted as Dean, Vice President for International Programs and Provost for the American University in Bosnia and Herzegovina. His lecturing and consulting interests are primarily in safety, leadership, team theory, and management."
Has the processing problem been solved?
"PROCESSING
The resource at the Dragon Mine is a mixture of a number of minerals including, but not limited to, halloysite, kaolinite and alunite. During 2005 and 2006, the Company invested in the development of a processing plant at the site of the Dragon Mine that was designed to separate tubular halloysite from non-halloysite material. The plant utilized an air-based processing technique. This method was ultimately deemed inadequate for the mineralogy of the Dragon Mine resource. As of the date of the filing of this Annual Report on Form 10-K, we signed a Memorandum of Understanding with KaMin upon which a binding toll manufacturing contract is to be developed."
Nail Polish Success with Halloysite Natural Tube Technology™. Fiabila Commits to Additional Orders.
ROCHESTER, N.Y., January 27, 2010
NaturalNano, Inc. (Pink Sheets: NNAN) (Frankfurt: N3N) announced today Fiabila S.A., a world leader in private label nail polish manufacture has committed to continue its use of NaturalNano’s environmentally friendly Halloysite Natural Tube (HNT) technology in their nail polish products.
Acting CEO & President James Wemett said” NNAN is very pleased with the technical and commercial success shown to date in the Fiabila nail polish product. We are very pleased with our association with Fiabila one of the world’s leading private manufacturer of nail enamels. The Fiabila manufactured products with HNT are available at most leading stores including Walmart, CVS and Walgreens.”
James Wemett continued, "This relationship with Fiabila represents a long term revenue opportunity for NaturalNano that utilizes our HNT™, which provides increased durability and performance to their nail polish products.” NaturalNano has a three year exclusive supply agreement and license with Fiabila for nail polish and nail-care products.
Pierre Miasnik, President of Fiabila commented, “NaturalNano’s technology has enabled us to continue to have an edge in the market place and to use Natural ingredients in our products for our customers.”
.....
"NaturalNano, Inc. (“NaturalNano”) has notified the Company that it believes it is in breach of an agreement entered with NaturalNano in 2004, which included the following:
1. The Company making available to NaturalNano a portion of its supply of unprocessed clay at the Dragon Mine, and;
2. A commitment by NaturalNano to process the clay at its expense, including an agreement by NaturalNano to provide, at its expenses, technical, financial and operating support to provide a particle separation and sizing process at the Dragon Mine site.
As consideration for the agreement, NaturalNano paid $250,000 to Atlas and Atlas issued 750,000 warrants to NaturalNano at an exercise price of $0.35.
NaturalNano has made a claim against the Company seeking to recover the $250,000 it believes is due to it as part of the 2004 transaction. The Company has made a counterclaim for monies received by NaturalNano from the sale of Atlas warrants issued to NaturalNano. As of the date of the filing of this report, NaturalNano has not filed a lawsuit. If a lawsuit were to be filed by NaturalNano, the Company would vigorously contest such a lawsuit."
Annual Report filed 3/31/2010 by Applied Minerals, Inc. (formerly Atlas Mining Company)
"The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant on March 29, 2010, based on the last sales price on the OTC Bulletin Board on that date, was approximately $58,616,335. The number of shares of the registrant’s common stock, $0.001 par value per share, outstanding as of December 31, 2009 was 69,781,351."
Annual Report filed 3/31/2010